Tiziana Life Sciences is showcasing its ongoing Phase 2a BANYAN Clinical Trial investigating intranasal foralumab, a fully human anti-CD3 monoclonal antibody, at ALS Nexus 2026. The presentation highlights the potential impact of innovative immunomodulation therapies in addressing ALS.